Besides screening HER2-positive lesions, some novel molecular imaging probes were designed to monitor the response to anti-HER2 treatment directly.249–251 In a preclinical study, 89Zr-pertuzumab accurately detected changes in tumor volume from 243.80 ± 40.91 mm3 before T-DM1 therapy to 78.4 ± 40.43 mm3 after this therapy in mice bearing BT-474 tumors. Here, ERBB2 is linked to neoplasm.